Stephen Gitelman, MD

Professor
Pediatrics
+1 415 476-3748

Stephen Gitelman, MD is the Director of the UCSF Pediatric Diabetes Program and has active clinical research interests in diabetes, particularly in the prevention of type 1 diabetes mellitus.

Publications: 

Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.

Diabetes, obesity & metabolism

O'Donnell HK, Simmons KM, Gitelman SE, Dex T, Hill R, Wieloch M, Zaccai J, D'Souza J, Ginchereau Sowell F, Turnbull J, Hood KK

Felix A. Conte, MD 1935-2024. The endocrinologist's endocrinologist.

Hormone research in paediatrics

Miller WL, Rosenthal SM, Gitelman SE, Lustig RH, Styne DM

Felix A. Conte, MD 1935-2024. The endocrinologist's endocrinologist.

Hormone research in paediatrics

Miller WL, Rosenthal SM, Gitelman SE, Lustig RH, Styne DM

Time to reframe the disease staging system for type 1 diabetes.

The lancet. Diabetes & endocrinology

Jacobsen LM, Atkinson MA, Sosenko JM, Gitelman SE

Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.

Diabetes care

Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM, Type 1 Diabetes TrialNet Study Group

A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.

Science translational medicine

Bender C, Wiedeman AE, Hu A, Ylescupidez A, Sietsema WK, Herold KC, Griffin KJ, Gitelman SE, Long SA, T-Rex Study Group†, T-Rex Clinical Study Group

The Role of Imatinib in Pediatric Type 1 Diabetes.

JCEM case reports

Lavelle K, Chamberlain C, German M, Anderson M, Nip A, Gitelman SE

Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice.

Hormone research in paediatrics

Mehta S, Ryabets-Lienhard A, Patel N, Breidbart E, Libman I, Haller MJ, Simmons KM, Sims EK, DiMeglio LA, Gitelman SE, Griffin KJ, Tonyushkina KN

Hydroxychloroquine in Stage 1 Type 1 Diabetes.

Diabetes care

Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC, Type 1 Diabetes TrialNet Study Group

Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.

The New England journal of medicine

Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC, PROTECT Study Investigators

Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review.

Communications medicine

Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GSF, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth JM, Redondo MJ, Sims EK, ADA/EASD PMDI

Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.

Nature medicine

Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, Duan D, Felton JL, Francis EC, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle JM, Jacobsen LM, Kahkoska AR, Kettunen JLT, Kreienkamp RJ, Lim LL, Männistö JME, Massey R, Mclennan NM, Miller RG, Morieri ML, Most J, Naylor RN, Ozkan B, Patel KA, Pilla SJ, Prystupa K, Raghavan S, Rooney MR, Schön M, Semnani-Azad Z, Sevilla-Gonzalez M, Svalastoga P, Takele WW, Tam CH, Thuesen ACB, Tosur M, Wallace AS, Wang CC, Wong JJ, Yamamoto JM, Young K, Amouyal C, Andersen MK, Bonham MP, Chen M, Cheng F, Chikowore T, Chivers SC, Clemmensen C, Dabelea D, Dawed AY, Deutsch AJ, Dickens LT, DiMeglio LA, Dudenhöffer-Pfeifer M, Evans-Molina C, Fernández-Balsells MM, Fitipaldi H, Fitzpatrick SL, Gitelman SE, Goodarzi MO, Grieger JA, Guasch-Ferré M, Habibi N, Hansen T, Huang C, Harris-Kawano A, Ismail HM, Hoag B, Johnson RK, Jones AG, Koivula RW, Leong A, Leung GKW, Libman IM, Liu K, Long SA, Lowe WL, Morton RW, Motala AA, Onengut-Gumuscu S, Pankow JS, Pathirana M, Pazmino S, Perez D, Petrie JR, Powe CE, Quinteros A, Jain R, Ray D, Ried-Larsen M, Saeed Z, Santhakumar V, Kanbour S, Sarkar S, Monaco GSF, Scholtens DM, Selvin E, Sheu WH, Speake C, Stanislawski MA, Steenackers N, Steck AK, Stefan N, Støy J, Taylor R, Tye SC, Ukke GG, Urazbayeva M, Van der Schueren B, Vatier C, Wentworth JM, Hannah W, White SL, Yu G, Zhang Y, Zhou SJ, Beltrand J, Polak M, Aukrust I, de Franco E, Flanagan SE, Maloney KA, McGovern A, Molnes J, Nakabuye M, Njølstad PR, Pomares-Millan H, Provenzano M, Saint-Martin C, Zhang C, Zhu Y, Auh S, de Souza R, Fawcett AJ, Gruber C, Mekonnen EG, Mixter E, Sherifali D, Eckel RH, Nolan JJ, Philipson LH, Brown RJ, Billings LK, Boyle K, Costacou T, Dennis JM, Florez JC, Gloyn AL, Gomez MF, Gottlieb PA, Greeley SAW, Griffin K, Hattersley AT, Hirsch IB, Hivert MF, Hood KK, Josefson JL, Kwak SH, Laffel LM, Lim SS, Loos RJF, Ma RCW, Mathieu C, Mathioudakis N, Meigs JB, Misra S, Mohan V, Murphy R, Oram R, Owen KR, Ozanne SE, Pearson ER, Perng W, Pollin TI, Pop-Busui R, Pratley RE, Redman LM, Redondo MJ, Reynolds RM, Semple RK, Sherr JL, Sims EK, Sweeting A, Tuomi T, Udler MS, Vesco KK, Vilsbøll T, Wagner R, Rich SS, Franks PW

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.

Diabetes care

Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.

Diabetes care

Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group

Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response.

medRxiv : the preprint server for health sciences

Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GS, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth JM, Redondo MJ, Sims EK

Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life.

Journal of diabetes science and technology

Chesser H, Srinivasan S, Puckett C, Gitelman SE, Wong JC

The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.

Diabetes care

Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J, DPT-1 and TrialNet Study Groups

IL-6 receptor blockade does not slow � cell loss in new-onset type 1 diabetes.

JCI insight

Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.

JCI insight

Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA

Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Diabetologia

Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

The lancet. Diabetes & endocrinology

Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group

Youth with Type 1 Diabetes Had Improvement in Continuous Glucose Monitoring Metrics During the COVID-19 Pandemic.

Diabetes technology & therapeutics

Abdulhussein FS, Chesser H, Boscardin WJ, Gitelman SE, Wong JC

Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.

Diabetes

Lin A, Mack JA, Bruggeman B, Jacobsen LM, Posgai AL, Wasserfall CH, Brusko TM, Atkinson MA, Gitelman SE, Gottlieb PA, Gurka MJ, Mathews CE, Schatz DA, Haller MJ

Continuous Glucose Monitoring to Diagnose Hypoglycemia Due to Late Dumping Syndrome in Children After Gastric Surgeries.

Journal of the Endocrine Society

Chesser H, Abdulhussein F, Huang A, Lee JY, Gitelman SE

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.

Diabetes technology & therapeutics

Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ

Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.

Diabetes, obesity & metabolism

Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS

Clinical trial data validate the C-peptide estimate model in type 1 diabetes.

Diabetologia

Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.

Diabetes care

Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.

JCI insight

Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD, RN168 Working Group

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Diabetes care

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M

Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome.

Xenotransplantation

Le Berre L, Danger R, Mai HL, Amon R, Leviatan Ben-Arye S, Bruneau S, Senage T, Perreault H, Teraiya M, Nguyen TVH, Le Tourneau T, Yu H, Chen X, Galli C, Roussel JC, Manez R, Costa C, Brouard S, Galinanes M, Harris KM, Gitelman S, Cozzi E, Charreau B, Padler-Karavani V, Soulillou JP

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

The New England journal of medicine

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Diabetes

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.

Diabetologia

Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC, Type 1 Diabetes TrialNet Study Group, Immune Tolerance Network Study Group

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves �-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Diabetes care

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group

Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy.

Oncotarget

Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V

The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.

The Journal of clinical endocrinology and metabolism

Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group

A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11.

Channels (Austin, Tex.)

Yang YY, Long RK, Ferrara CT, Gitelman SE, German MS, Yang SB

Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.

Transplantation

Salama A, Evanno G, Lim N, Rousse J, Le Berre L, Nicot A, Bach JM, Brouard S, Harris KM, Ehlers MR, Gitelman SE, Soulillou JP

Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?

Diabetes care

Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group

Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.

Diabetes care

Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.

Diabetes

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA

Regulatory T cell therapy for type 1 diabetes: May the force be with you.

Journal of autoimmunity

Gitelman SE, Bluestone JA

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes.

Diabetes care

Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2�year results of a randomised trial.

Diabetologia

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START Study Team

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Science translational medicine

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Diabetes care

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

The Journal of clinical investigation

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR

Anti-thymocyte globulin/G-CSF treatment preserves � cell function in patients with established type 1 diabetes.

The Journal of clinical investigation

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA

Recommendations for the definition of clinical responder in insulin preservation studies.

Diabetes

Beam CA, Gitelman SE, Palmer JP, Type 1 Diabetes TrialNet Study Group

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.

Diabetes care

Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

The lancet. Diabetes & endocrinology

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, T1DAL Study Team

B-lymphocyte depletion with rituximab and �-cell function: two-year results.

Diabetes care

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

The lancet. Diabetes & endocrinology

Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, START Study Team

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Diabetes

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team

Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Benedict KA, Moassesfar S, Adi S, Gitelman SE, Brennan JL, McEnhill M, Stock PG, Portale AA, Posselt AM

Comparison of autoantibody-positive and autoantibody-negative pediatric participants enrolled in the T1D Exchange clinic registry.

Journal of diabetes

Gerard-Gonzalez A, Gitelman SE, Cheng P, Dubose SN, Miller KM, Olson BA, Redondo MJ, Steck AK, Beck RW

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Lancet (London, England)

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, B?ehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Casta?o L, W?gner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group

A cross-sectional study of osteocalcin and body fat measures among obese adolescents.

Obesity (Silver Spring, Md.)

Lenders CM, Lee PD, Feldman HA, Wilson DM, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF, Elisabeth Glaser Pediatric Research Network Obesity Study Group

Immune therapy and �-cell death in type 1 diabetes.

Diabetes

Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

Diabetologia

Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Diabetes

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Lancet (London, England)

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Lancet (London, England)

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group

Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population?

Pediatric diabetes

Glaser NS, Geller DH, Haqq A, Gitelman S, Malloy M, Lawson Wilkins Pediatric Endocrine Society Committee on Drugs and Therapeutics

Impact of an interactive online nursing educational module on insulin errors in hospitalized pediatric patients.

Diabetes care

Sullivan MM, O'Brien CR, Gitelman SE, Shapiro SE, Rushakoff RJ

Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.

Molecular pharmacology

Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M

Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis.

International journal of pediatric endocrinology

Cho YH, Gitelman S, Rosenthal S, Ambler G

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

The New England journal of medicine

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group

Relation of body fat indexes to vitamin D status and deficiency among obese adolescents.

The American journal of clinical nutrition

Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF, Elizabeth Glaser Pediatric Research Network Obesity Study Group

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Clinical immunology (Orlando, Fla.)

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group

Congenital hyperinsulinism in an infant caused by a macroscopic insulin-producing lesion.

Journal of pediatric endocrinology & metabolism : JPEM

Bremer AA, Nobuhara KK, Gitelman SE

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction.

Pediatric endocrinology reviews : PER

Rosenthal SM, Feldman BJ, Vargas GA, Gitelman SE

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.

Diabetes

Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC

Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.

The American journal of medicine

Gitelman SE, Feldman BJ, Rosenthal SM

Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children.

The Journal of pediatrics

Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE

Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis.

Journal of pediatric endocrinology & metabolism : JPEM

Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Diabetes

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA

Nephrogenic syndrome of inappropriate antidiuresis.

The New England journal of medicine

Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE

A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes.

Diabetes care

Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE

The use of a continuous glucose monitoring system in hypoglycemic disorders.

Journal of pediatric endocrinology & metabolism : JPEM

Conrad SC, Mastrototaro JJ, Gitelman SE

Insulin secretion in type 1 diabetes.

Diabetes

Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

The New England journal of medicine

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA

Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis.

Pediatric nephrology (Berlin, Germany)

Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS

Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients.

Diabetologia

Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S

Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass.

Development (Cambridge, England)

Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R

Neonatal hyperinsulinism.

Clinics in perinatology

Schwitzgebel VM, Gitelman SE

Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease.

The Journal of clinical endocrinology and metabolism

Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE

Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents.

The Journal of clinical endocrinology and metabolism

Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA

Structure and sequence of the mouse Bmp6 gene.

Mammalian genome : official journal of the International Mammalian Genome Society

Gitelman SE, Kobrin M, Lee A, Fet V, Lyons K, Hogan BL, Derynck R

Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells.

Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research

Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ, Derynck R

Toward a molecular understanding of skeletal development.

Cell

Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R

Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo.

The Journal of cell biology

Gitelman SE, Kobrin MS, Ye JQ, Lopez AR, Lee A, Derynck R

Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B.

The Journal of cell biology

Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL

Abundant adrenal-specific transcription of the human P450c21A "pseudogene".

The Journal of biological chemistry

Bristow J, Gitelman SE, Tee MK, Staels B, Miller WL

Mental retardation locus in Xp21 chromosome microdeletion.

American journal of medical genetics

Fries MH, Lebo RV, Schonberg SA, Golabi M, Seltzer WK, Gitelman SE, Golbus MS

Congenital lipoid adrenal hyperplasia--genes for P450scc, side chain cleavage enzyme, are normal.

The Journal of steroid biochemistry and molecular biology

Saenger P, Lin D, Gitelman SE, Miller WL

Analysis of the duplicated human C4/P450c21/X gene cluster.

The Journal of steroid biochemistry and molecular biology

Miller WL, Gitelman SE, Bristow J, Morel Y

Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus.

Molecular and cellular biology

Gitelman SE, Bristow J, Miller WL

Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus.

Molecular and cellular biology

Gitelman SE, Bristow J, Miller WL

Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia.

The Journal of clinical investigation

Lin D, Gitelman SE, Saenger P, Miller WL

Cloning of the LH/CG receptor: implications for a unique G-protein coupled receptor.

Trends in endocrinology and metabolism: TEM

Gitelman SE

Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus.

Proceedings of the National Academy of Sciences of the United States of America

Morel Y, Bristow J, Gitelman SE, Miller WL